Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 4492 | 314.7 |
09:36 ET | 1000 | 316.075 |
09:39 ET | 350 | 315.9 |
09:43 ET | 100 | 316.48 |
09:45 ET | 400 | 316.47 |
09:48 ET | 800 | 316.45 |
09:50 ET | 186 | 316.435 |
09:54 ET | 536 | 315.655 |
09:56 ET | 350 | 316.415 |
09:57 ET | 216 | 316.525 |
10:03 ET | 1600 | 316.205 |
10:06 ET | 100 | 316.37 |
10:08 ET | 1626 | 317.3041 |
10:10 ET | 1598 | 316.98 |
10:12 ET | 4719 | 317.54 |
10:14 ET | 3613 | 316.435 |
10:15 ET | 456 | 315.43 |
10:24 ET | 405 | 314.81 |
10:26 ET | 200 | 315.085 |
10:28 ET | 4034 | 313.755 |
10:30 ET | 1019 | 313.8 |
10:32 ET | 625 | 314.315 |
10:33 ET | 430 | 315.24 |
10:35 ET | 350 | 315.24 |
10:37 ET | 100 | 314.39 |
10:39 ET | 975 | 314.81 |
10:44 ET | 100 | 314.815 |
10:46 ET | 300 | 315.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 14.2B | 14.9x | +8.22% |
Biomarin Pharmaceutical Inc | 16.1B | 79.0x | --- |
Beigene Ltd | 16.5B | -19.2x | --- |
Neurocrine Biosciences Inc | 13.6B | 37.2x | +62.04% |
Medpace Holdings Inc | 12.6B | 42.2x | +35.10% |
Exact Sciences Corp | 8.1B | -33.2x | --- |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.2B |
---|---|
Revenue (TTM) | $2.5B |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.56 |
EPS | $21.13 |
Book Value | $127.23 |
P/E Ratio | 14.9x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | 12.8x |
Operating Margin | 50.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.